Arbitrary Restriction Polymorphism 1 Clinical Trial
Official title:
Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia
The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.
The purpose of this study was to evaluate the influence of severe acute pancreatitis on the
serum level of vancomycin, a glycopeptide antibacterial agent.
After reviewing more than 6000 clinical charts of patients who received vancomycin therapy
and whose serum vancomycin level was monitored between January 2010 and December 2013, we
identified 212 patients who also had diagnosed as severe acute pancreatitis (SAP group), and
98 patients who also had diagnosed as pneumonia (pneumonia group) at that time. The
fluorescence polarization immunoassay method was used to measure vancomycin serum trough
concentrations in these patients 30 min before the next administration. Using these
measurements, we calculated the pharmacokinetic parameters using the Bayesian estimator.
;
Observational Model: Case Control, Time Perspective: Retrospective